Elevated levels of endocannabinoids in chronic hepatitis c may modulate cellular immune response and hepatic stellate cell activation

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 7057-7076

  Patsenker, Eleonora ^a   Sachse, Philip ^a   Chicca, Andrea ^a   Gachet, María Salomé ^a   Schneider, Vreni ^a   Mattsson, Johan ^a   Lanz, Christian ^a   Worni, Mathias ^a   De Gottardi, Andrea ^a   Semmo, Mariam ^a   Hampe, Jochen ^b   Schafmayer, Clemens ^c   Brenneisen, Rudolf ^a   Gertsch, Jürg ^a   Stickel, Felix ^a   Semmo, Nasser ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Endocannabinoid system; Fibrosis; Hepatitis C; Inflammation; Liver; Peripheral blood mononuclear cells

Indexed keywords

ACYLGLYCEROL LIPASE; ANANDAMIDE; CYCLOOXYGENASE 2; ENDOCANNABINOID; FATTY ACID AMIDASE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; ACYLGLYCEROL; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CYTOKINE; FATTY-ACID AMIDE HYDROLASE; GLYCERYL 2-ARACHIDONATE;

ARTICLE; BODY MASS; CANNABIS ADDICTION; CELL ACTIVATION; CELLULAR IMMUNITY; CHRONIC HEPATITIS C; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; ADULT; BLOOD; CELL CULTURE; ENZYMOLOGY; HEPATIC STELLATE CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AMIDOHYDROLASES; ARACHIDONIC ACIDS; CELLS, CULTURED; CYTOKINES; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; MONOACYLGLYCEROL LIPASES; POLYUNSATURATED ALKAMIDES;

EID: 84942835322     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16047057     Document Type: Article

References (44)

1. Nagarkatti, P.; Pandey, R.; Rieder, S. A.; Hegde, V. L.; Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 2009, 1, 1333–1349.
2. Julien, B.; Grenard, P.; Teixeira-Clerc, F.; van Nhieu, J. T.; Li, L.; Karsak, M.; Zimmer, A.; Mallat, A.; Lotersztajn, S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005, 128, 742–755.
3. Pacher, P.; Gao, B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: Implications for inflammatory liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G850–G854.
4. Guillot, A.; Hamdaoui, N.; Bizy, A.; Zoltani, K.; Souktani, R.; Zafrani, E. S.; Mallat, A.; Lotersztajn, S.; Lafdil, F. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 2014, 59, 296–306.
5. Teixeira-Clerc, F.; Julien, B.; Grenard, P.; Tran Van Nhieu, J.; Deveaux, V.; Li, L.; Serriere-Lanneau, V.; Ledent, C.; Mallat, A.; Lotersztajn, S. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat. Med. 2006, 12, 671–676.
6. Mallat, A.; Teixeira-Clerc, F.; Deveaux, V.; Manin, S.; Lotersztajn, S. The endocannabinoid system as a key mediator during liver diseases: New insights and therapeutic openings. Br. J. Pharmacol. 2011, 163, 1432–1440.
7. Caraceni, P.; Viola, A.; Piscitelli, F.; Giannone, F.; Berzigotti, A.; Cescon, M.; Domenicali, M.; Petrosino, S.; Giampalma, E.; Riili, A.; et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int. 2009, 30, 816–825.
8. Biswas, K. K.; Sarker, K. P.; Abeyama, K.; Kawahara, K.; Iino, S.; Otsubo, Y.; Saigo, K.; Izumi, H.; Hashiguchi, T.; Yamakuchi, M.; et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003, 38, 1167–1177.
9. Osei-Hyiaman, D.; DePetrillo, M.; Pacher, P.; Liu, J.; Radaeva, S.; Batkai, S.; Harvey-White, J.; Mackie, K.; Offertaler, L.; Wang, L.; et al. Endocannabinoid activation at hepatic cb1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Investig. 2005, 115, 1298–1305.
10. Siegmund, S. V.; Seki, E.; Osawa, Y.; Uchinami, H.; Cravatt, B. F.; Schwabe, R. F. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem. 2006, 281, 10431–10438.
11. Baldassarre, M.; Giannone, F. A.; Napoli, L.; Tovoli, A.; Ricci, C. S.; Tufoni, M.; Caraceni, P. The endocannabinoid system in advanced liver cirrhosis: Pathophysiological implication and future perspectives. Liver Int. 2013, 33, 1298–1308.
12. Cencioni, M. T.; Chiurchiu, V.; Catanzaro, G.; Borsellino, G.; Bernardi, G.; Battistini, L.; Maccarrone, M. Anandamide suppresses proliferation and cytokine release from primary human t-lymphocytes mainly via CB2 receptors. PLoS ONE 2010, 5, e8688.
13. Pandey, R.; Hegde, V. L.; Singh, N. P.; Hofseth, L.; Singh, U.; Ray, S.; Nagarkatti, M.; Nagarkatti, P. S. Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam. Horm. 2009, 81, 487–504.
14. Hegde, V. L.; Hegde, S.; Cravatt, B. F.; Hofseth, L. J.; Nagarkatti, M.; Nagarkatti, P. S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory t cells. Mol. Pharmacol. 2008, 74, 20–33.
15. Klein, T. W.; Newton, C.; Larsen, K.; Chou, J.; Perkins, I.; Lu, L.; Nong, L.; Friedman, H. Cannabinoid receptors and T helper cells. J. Neuroimmunol. 2004, 147, 91–94.
16. Klein, T. W.; Newton, C.; Larsen, K.; Lu, L.; Perkins, I.; Nong, L.; Friedman, H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 2003, 74, 486–496.
17. Rockwell, C. E.; Snider, N. T.; Thompson, J. T.; Vanden Heuvel, J. P.; Kaminski, N. E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 2006, 70, 101–111.
18. Louvet, A.; Teixeira-Clerc, F.; Chobert, M. N.; Deveaux, V.; Pavoine, C.; Zimmer, A.; Pecker, F.; Mallat, A.; Lotersztajn, S. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice. Hepatology 2011, 54, 1217–1226.
19. Zhou, L.; Ding, L.; Yin, P.; Lu, X.; Wang, X.; Niu, J.; Gao, P.; Xu, G. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. J. Proteome Res. 2012, 11, 5433–5442.
20. Mallat, A.; Teixeira-Clerc, F.; Lotersztajn, S. Cannabinoid signaling and liver therapeutics. J. Hepatol. 2013, 59, 891–896.
21. Ishida, J. H.; Peters, M. G.; Jin, C.; Louie, K.; Tan, V.; Bacchetti, P.; Terrault, N. A. Influence of cannabis use on severity of hepatitis c disease. Clin. Gastroenterol. Hepatol. 2008, 6, 69–75.
22. Hezode, C.; Roudot-Thoraval, F.; Nguyen, S.; Grenard, P.; Julien, B.; Zafrani, E. S.; Pawlotsky, J. M.; Dhumeaux, D.; Lotersztajn, S.; Mallat, A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis c. Hepatology 2005, 42, 63–71.
23. Hezode, C.; Zafrani, E. S.; Roudot-Thoraval, F.; Costentin, C.; Hessami, A.; Bouvier-Alias, M.; Medkour, F.; Pawlostky, J. M.; Lotersztajn, S.; Mallat, A. Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis c. Gastroenterology 2008, 134, 432–439.
24. Van der Poorten, D.; Shahidi, M.; Tay, E.; Sesha, J.; Tran, K.; McLeod, D.; Milliken, J. S.; Ho, V.; Hebbard, L. W.; Douglas, M. W.; et al. Hepatitis C virus induces the cannabinoid receptor 1. PLoS ONE 2010, 5, e12841.
25. Parfieniuk, A.; Flisiak, R. Role of cannabinoids in chronic liver diseases. World J. Gastroenterol. 2008, 14, 6109–6114.
26. Siegmund, S. V.; Schwabe, R. F. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G357–G362.
27. Clugston, R. D.; Jiang, H.; Lee, M. X.; Piantedosi, R.; Yuen, J. J.; Ramakrishnan, R.; Lewis, M. J.; Gottesman, M. E.; Huang, L. S.; Goldberg, I. J.; et al. Altered hepatic lipid metabolism in c57bl/6 mice fed alcohol: A targeted lipidomic and gene expression study. J. Lipid Res. 2011, 52, 2021–2031.
28. Balvers, M. G.; Verhoeckx, K. C.; Meijerink, J.; Bijlsma, S.; Rubingh, C. M.; Wortelboer, H. M.; Witkamp, R. F. Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in c57bl/6 mice fed a fish-oil diet. Int. Immunopharmacol. 2012, 13, 204–214.
29. Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 2007, 18, 129–140.
30. Hauer, D.; Schelling, G.; Gola, H.; Campolongo, P.; Morath, J.; Roozendaal, B.; Hamuni, G.; Karabatsiakis, A.; Atsak, P.; Vogeser, M.; et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS ONE 2013, 8, e62741.
31. Sun, L. J.; Yu, J. W.; Wan, L.; Zhang, X. Y.; Shi, Y. G.; Chen, M. Y. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. Int. J. Infect. Dis. 2014, 23, 75–81.
32. Shahidi, M.; Tay, E. S.; Read, S. A.; Ramezani-Moghadam, M.; Chayama, K.; George, J.; Douglas, M. W. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agents. J. Gen. Virol. 2014, 95, 2468–2479.
33. Patsenker, E.; Stoll, M.; Millonig, G.; Agaimy, A.; Wissniowski, T.; Schneider, V.; Mueller, S.; Brenneisen, R.; Seitz, H. K.; Ocker, M.; et al. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol. Med. 2011, 17, 1285–1294.
34. Mueller, M.; Spangenberg, H. C.; Kersting, N.; Altay, T.; Blum, H. E.; Klenerman, P.; Thimme, R.; Semmo, N. Virus-specific cd4+ T cell responses in chronic hcv infection in blood and liver identified by antigen-specific upregulation of cd154. J. Hepatol. 2010, 52, 800–811.
35. Glassner, A.; Eisenhardt, M.; Kokordelis, P.; Kramer, B.; Wolter, F.; Nischalke, H. D.; Boesecke, C.; Sauerbruch, T.; Rockstroh, J. K.; Spengler, U.; et al. Impaired CD4+ T cell stimulation of nk cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J. Hepatol. 2013, 59, 427–433.
36. Schwabe, R. F.; Siegmund, S. V. Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. Hepatology 2005, 42, 975–976; author reply 976–977.
37. Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce? Nat. Rev. Drug Discov. 2008, 7, 438–455.
38. Cao, Z.; Mulvihill, M. M.; Mukhopadhyay, P.; Xu, H.; Erdelyi, K.; Hao, E.; Holovac, E.; Hasko, G.; Cravatt, B. F.; Nomura, D.K.; et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144, 808–817.
39. Von Schonfels, W.; Patsenker, E.; Fahrner, R.; Itzel, T.; Hinrichsen, H.; Brosch, M.; Erhart, W.; Gruodyte, A.; Vollnberg, B.; Richter, K.; et al. Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. Liver Int. 2014, 35, 207–214.
40. Semmo, N.; Krashias, G.; Willberg, C.; Klenerman, P. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J. Viral Hepat. 2007, 14, 492–502.
41. Chicca, A.; Marazzi, J.; Nicolussi, S.; Gertsch, J. Evidence for bidirectional endocannabinoid transport across cell membranes. J. Biol. Chem. 2012, 287, 34660–34682.
42. Patsenker, E.; Popov, Y.; Stickel, F.; Jonczyk, A.; Goodman, S. L.; Schuppan, D. Inhibition of integrin αvβ6 on cholangiocytes blocks transforming growth factor-β activation and retards biliary fibrosis progression. Gastroenterology 2008, 135, 660–670.
43. Semmo, N.; Barnes, E.; Taylor, C.; Kurtz, J.; Harcourt, G.; Smith, N.; Klenerman, P. T-cell responses and previous exposure to hepatitis c virus in indeterminate blood donors. Lancet 2005, 365, 327–329.
44. Semmo, N.; Day, C. L.; Ward, S. M.; Lucas, M.; Harcourt, G.; Loughry, A.; Klenerman, P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005, 41, 1019–1028.